These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 12766730

  • 1. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
    Dickstein K.
    Am Heart J; 2003 May; 145(5):754-7. PubMed ID: 12766730
    [No Abstract] [Full Text] [Related]

  • 2. The OPTIMAAL study, not so optimal: the lessons of LIFE, RENAAL and IDNT.
    Lapointe N, Pourdjabbar A, Rouleau JL.
    Can J Cardiol; 2003 Aug; 19(9):994-6. PubMed ID: 12915925
    [No Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 4. [ELITE II. AT1-blockers not better, but more tolerable than ACE-inhibitors].
    Berger D.
    Internist (Berl); 2000 Jan; 41(1):A37. PubMed ID: 10712087
    [No Abstract] [Full Text] [Related]

  • 5. [Suboptimal results of Optimaal: treatment with ACE inhibitors remains the preferred therapy in patients with left ventricular dysfunction after acute myocardial infarct]].
    Danchin N.
    Herz; 2002 Dec; 27(8):(18). PubMed ID: 12608391
    [No Abstract] [Full Text] [Related]

  • 6. [A-II blocker or ACE inhibitor in heart failure? Captopril can't be beat].
    Einecke D.
    MMW Fortschr Med; 1999 Nov 25; 141(47):4-5. PubMed ID: 10912155
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
    Dickstein K, Kjekshus J, OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
    Am J Cardiol; 2001 Mar 15; 87(6):766-71, A7. PubMed ID: 11249900
    [Abstract] [Full Text] [Related]

  • 8. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
    Belonje AM, Westenbrink BD, Voors AA, von Haehling S, Ponikowski P, Anker SD, van Veldhuisen DJ, Dickstein K.
    Am Heart J; 2009 Jan 15; 157(1):91-6. PubMed ID: 19081402
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
    Dickstein K, Kjekshus J.
    Am J Cardiol; 1999 Feb 15; 83(4):477-81. PubMed ID: 10073846
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin II type 1 receptor blockers and congestive heart failure.
    Auer JW, Berent R, Eber B.
    Circulation; 2001 Oct 09; 104(15):E82. PubMed ID: 11591633
    [No Abstract] [Full Text] [Related]

  • 11. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.
    Møller JE, Dahlström U, Gøtzsche O, Lahiri A, Skagen K, Andersen GS, Egstrup K, OPTIMAAL Study Group.
    Am Heart J; 2004 Mar 09; 147(3):494-501. PubMed ID: 14999200
    [Abstract] [Full Text] [Related]

  • 12. [Current role of angiotensin II antagonists in the treatment of heart failure].
    Porcu M, Orrù P.
    Ital Heart J Suppl; 2000 Sep 09; 1(9):1213-4. PubMed ID: 11140296
    [No Abstract] [Full Text] [Related]

  • 13. [New options against undertreatment].
    Pfeffer M.
    MMW Fortschr Med; 2003 Dec 04; 145(49):18. PubMed ID: 14963987
    [No Abstract] [Full Text] [Related]

  • 14. Is losartan superior to captopril in reducing all-cause mortality in elderly patients with symptomatic heart failure?
    Trojian TH, Jackson EA.
    J Fam Pract; 2000 Aug 04; 49(8):759-60. PubMed ID: 10947144
    [No Abstract] [Full Text] [Related]

  • 15. The OPTIMAAL trial: losartan or captopril after acute myocardial infarction.
    Gayet JL, Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
    Lancet; 2002 Dec 07; 360(9348):1884-5; author reply 1885. PubMed ID: 12480392
    [No Abstract] [Full Text] [Related]

  • 16. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 17. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
    MMW Fortschr Med; 2003 Oct 23; 145(43):51. PubMed ID: 14664222
    [No Abstract] [Full Text] [Related]

  • 18. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
    Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group.
    Lancet; 2002 Sep 07; 360(9335):752-60. PubMed ID: 12241832
    [Abstract] [Full Text] [Related]

  • 19. ACE inhibitors or AT-1 antagonists - which is OPTIMAAL after acute myocardial infarction?
    Doggrell SA.
    Expert Opin Pharmacother; 2003 Mar 07; 4(3):407-9. PubMed ID: 12614193
    [Abstract] [Full Text] [Related]

  • 20. Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of Losartan In The Elderly.
    Berry C, Norrie J, McMurray JJ.
    Am J Cardiol; 2001 Mar 01; 87(5):606-7, A9. PubMed ID: 11230847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.